In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zeneca's PBM Alternative

Executive Summary

Zeneca, in tying up with Salick, won’t in the near term build up sales volumes of its cancer drugs. It’s hoping that Salick’s database will provide product-differentiating information for its pharmaceuticals and let it explore the service business, which, in a capitated system, could increase in profitability as pharmaceuticals shrink. And while Salick's facilities-based approach to cancer treatment means its system will be more difficult to expand than a facilities-independent cancer management system, it could also provide a template for disease management in other therapeutic areas.

You may also be interested in...



Reinventing Pharmacy: The Price Increase for Caremark Could Be a Price Decrease for Manufacturers

The battle between CVS and Express Scripts for ownership of Caremark has made little impact on drug-company executives. But there is an important implication for pricing in the Medicare Part D world: CVS wants to use Caremark to help it get higher payments for providing pharmacy services. But in the zero-sum game of reimbursement, any additional profits for chains will likely come from reduced prices on drugs.

HBW Product Launches: VitaFusion Goodness, Colgate Zero, Tom’s Prebiotic, Gaia Hemp & Herb

Colgate Zero toothpastes and mouthwashes promote what’s missing; Tom’s of Maine natural personal care expands with prebiotic toothpaste, deodorant and hand soap; Gaia adds hemp to its herbs; and Church & Dwight goes environmentally friendly with VitaFusion Goodness supplements, adds CBD versions to line, too.

High-Priced Entries Drive 17% Rise In Spending On Anti-Inflammatory Drugs

But declines in other categories held overall spending on US retail pharmacy drugs covered by commercial plans to a marginal 2.3% increase in 2019, Express Scripts reports.

Topics

Related Companies

UsernamePublicRestriction

Register

IV000173

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel